Swoop Creates Patient Advocacy and Privacy Advisory Board

Advisors to guide company’s patient outcomes-driven technology development

CAMBRIDGE, MA. – May 16, 2019 – Swoop, the company driving better patient outcomes through AI-generated digital audiences for the life sciences industry, today announced a newly-formed Patient Advocacy and Privacy Advisory Board. The formation of the Board empowers Swoop to continue being at the forefront of using the constantly-improving power of AI and digital messaging for patient engagement while protecting consumer rights and lowering healthcare costs.

Members of the Board include: Patricia Bailin, Head of Privacy and Data Ethics of Datavant, previously a Privacy Officer for LiveRamp and the Director of Privacy for Product and Engineering at Acxiom; Jennifer Beachell – former President of US Commercial at Aegerion Pharmaceuticals, VP of Marketing and Market Access at Welldoc; and Jodie Sherman Gillon – Global Medical Lead, Patient Engagement Rare Diseases, Pfizer.

“The ability of data-driven technology companies to predict and shape patient outcomes creates both an opportunity and a responsibility to uphold and protect patient and consumer privacy”, said Patricia Bailin. “The lack of regulatory and guidelines in this emerging area complicates matters, as questions such as “What is a positive patient outcome, and who sets the standard?”, “What data is acceptable to use in order to make predictions, and who decides?” exist in a grey area with no clearly defined answers”.

“Developing criteria for determining sensitive health conditions where advertising requires consumer opt-in consent allows Swoop to help shape an environment where consumers are provided with clear notice and choice”. said Jennifer Beachell. “We believe that this is the best way to integrate strong privacy protections with ethical and effective use of machine learning and artificial intelligence for the benefit of consumers, the biopharma industry and society as a whole.

Swoop has invested significant resources and effort to improve patient outcomes without sacrificing patient privacy building on our founders’ work with Evidon/Ghostery, the first system designed to give consumers control over their online data and choices; our participation as founding members of TAG, the Trustworthiness Accountability Group; our involvement with IAB’s Data Transparency Standards Working Group; our participation in the Health Working Group at the Future of Privacy Forum; and the development of our best-in-class HIPAA-certified privacy platform.

 

About Swoop
Swoop empowers the world’s leading healthcare and life sciences organizations to better educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement precisely engages ideal patient populations through cross-channel marketing strategies by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data pool of over 300 million de-identified patients and a behavioral data stream of over 65 billion anonymous consumer transactions.

Media Contact
John Seaner
Chief Marketing Officer
Swoop
john@swoop.com
+1 267-247-6323

Related Posts

Mar-2-2020 Press Release
Swoop Granted Patent for Privacy by Design Data Processing Technique

Expands the use of artificial intelligence to positively influence health outcomes without sacrificing patient privacy

Jan-14-2020 Press Release
Swoop Becomes the First Consumer Health Data Company to Join NAI

Company at the forefront of protecting patient privacy without sacrificing ability to improve health outcomes

Leave a Reply